VTRS
Viatris Inc

3,782
Mkt Cap
$12.3B
Volume
3.44M
52W High
$13.55
52W Low
$6.85
PE Ratio
-3.38
VTRS Fundamentals
Price
$10.23
Prev Close
$10.46
Open
$10.48
50D MA
$10.16
Beta
0.76
Avg. Volume
7.32M
EPS (Annual)
-$0.5315
P/B
0.80
Rev/Employee
$459,678.13
Loading...
Loading...
News
all
press releases
Ex-Dividend Reminder: Viatris, Radian Group and Equitable Holdings
Looking at the universe of stocks we cover at Dividend Channel, on 11/24/25, Viatris Inc (Symbol: VTRS), Radian Group, Inc. (Symbol: RDN), and Equitable Holdings Inc (Symbol: EQH) will all trade...
Nasdaq News: Markets·5h ago
News Placeholder
More News
News Placeholder
ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?
ANIP's 53% YTD surge fuels strong 2025 financial performance, a raised outlook and powerful momentum in its rare disease portfolio.
Zacks·6d ago
News Placeholder
Viatris Recognized as One of the Fortune World's Best Workplaces in 2025
Viatris Recognized as One of the Fortune World's Best Workplaces in 2025 Viatris Recognized as One of the Fortune World's Best Workplaces in 2025 PR Newswire PITTSBURGH, Nov. 13, 2025 PITTSBURGH...
PR Newswire·7d ago
News Placeholder
Daily Market Wrap: Paramount Skydance, CoreWeave, and SoftBank
The market had a mixed performance on Tuesday, Nov. 11, with tech stocks underperforming as a ripple effect of Nvidia's lackluster performance. The S&P 500 was up 0.2% at the close, led by surprise...
TheStreet.com·9d ago
News Placeholder
Tuesday Sector Leaders: Healthcare, Energy
The best performing sector as of midday Tuesday is the Healthcare sector, up 1.8%. Within the sector, Viatris Inc (Symbol: VTRS) and Moderna Inc (Symbol: MRNA) are two large stocks leading the way...
Nasdaq News: Markets·9d ago
News Placeholder
Theravance's Q3 Earnings Surpass Estimates, Revenues Match
TBPH delivers a third-quarter profit, beating estimates, and 19% revenue growth, fueled by rising collaboration income from Viatris related to Yupelri sales.
Zacks·9d ago
News Placeholder
Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance
Viatris tops Q3 earnings and revenue estimates, lifts 2025 outlook, and expands its Japan presence with Aculys Pharma deal.
Zacks·14d ago
News Placeholder
Viatris (VTRS) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·14d ago
News Placeholder
Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates
Viatris (VTRS) delivered earnings and revenue surprises of +6.35% and +3.09%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago
News Placeholder
Countdown to Viatris (VTRS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Viatris (VTRS) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Zacks·15d ago

Latest VTRS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.